drugset / Trial / NCT04008888
a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The clinical trial was conducted in a cohort of young, high-risk myeloma patients who were designed to receive a combination of high-dose chemotherapy with allogeneic or autologous hematopoietic stem cell transplantation. The objective was to assess the progression free survival (PFS), overall survival (OS),and overall response rate (ORR) of the overall treatment.
Timeline
- Start
- 2018-01-05
- Primary completion
- 2020-01-01
- Completion
- 2020-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fludarabine | Small molecule | 30 mg/m2 | Intravenous |
| Subject | Lenalidomide | Other / unclassified | 25 mg | Oral |
| Subject | Melphalan | Small molecule | 70 mg/m2 | Intravenous |
| Subject | Melphalan | Small molecule | 200 mg/m2 | Intravenous |
| Background | Bortezomib | Small molecule | — | — |
| Background | Dexamethasone | Small molecule | 20 mg | — |
| Background | Ixazomib | Unknown | — | — |